SCHEMBL650929

SCHEMBL650929

Cc1ccc(/N=C2/NC(=O)/C(=C/c3cnc(NCCCN4CCOCC4)s3)S2)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.48
NPSR1 Q6W5P4 4/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
TDP1 Q9NUW8 3/20 0.48
MAPK1 P28482 2/20 0.48
RECQL P46063 1/20 0.47
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
LMNA P02545 2/20 0.44
KMT2A Q03164 7/20 0.43
MEN1 O00255 4/20 0.43
PKM P14618 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ALDH1A1 P00352 2/20 0.40
HTT P42858 1/20 0.38
RNASEL Q05823 1/20 0.38
RAD52 P43351 1/20 0.36
UHRF1 Q96T88 1/20 0.36
KDM4E B2RXH2 2/20 0.36
EGFR P00533 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650930 1.00 MAPT (0.48) MAPTNPSR1L3MBTL1TDP1MAPK1
SCHEMBL653415 0.93 MAPT (0.50) MAPTNPSR1L3MBTL1TDP1MAPK1
SCHEMBL10226368 0.93 MAPT (0.50) MAPTNPSR1L3MBTL1TDP1MAPK1
SCHEMBL650125 0.92 KMT2A (0.42) MAPTNPSR1L3MBTL1TDP1MAPK1
SCHEMBL650124 0.92 KMT2A (0.42) MAPTNPSR1L3MBTL1TDP1MAPK1
SCHEMBL10227933 0.88 MAPT (0.51) MAPTNPSR1L3MBTL1TDP1MAPK1
SCHEMBL652066 0.88 MAPT (0.51) MAPTNPSR1L3MBTL1TDP1MAPK1
SCHEMBL649998 0.87 CDC25A (0.43) MAPTL3MBTL1TDP1MAPK1HPGD
SCHEMBL648672 0.87 CDC25A (0.43) MAPTL3MBTL1TDP1MAPK1HPGD
SCHEMBL10176363 0.85 MAPT (0.41) MAPTNPSR1L3MBTL1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
WO-2010122979-A1 THIAZOLIDINONE DERIVATIVE SBIバイオテック株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885NPSR1 4464/4885L3MBTL1 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.